Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: Three double-blind, randomized, placebo- controlled trials

Archives of Neurology

Volumn 55, Issue 2, 1998, Pages 210-217

  Lipton, Richard B ^a,c,h   Stewart, Walter F ^b,c   Ryan Jr , Robert E ^d   Saper, Joel ^e   Silberstein, Stephen ^f   Sheftell, Fred ^g  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Innovative Medical Research   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Michigan Headache Pain and Neurological Institute   (United States)

^f Comprehensive Headache Center ^*  (United States)

^g NEW ENGLAND CENTER FOR HEADACHE   (United States)

^h MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CAFFEINE; EXCEDRIN; PARACETAMOL; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIGRAINE; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACETAMINOPHEN; ADULT; ANALGESICS; ASPIRIN; CAFFEINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0031912064     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.2.210     Document Type: Article

References (26)

1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267:64-69.
2. Rasmussen BK, Breslau N. Migraine: epidemiology. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York, NY: Raven Press; 1993:169-173.
3. Stewart WF, Schecter A, Lipton RB. Migraine heterogeneity: disability, pain intensity, and attack frequency and duration. Neurology. 1994;44(suppl 4):S24-S39.
4. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology. 1993:43(suppl 3):S6-S10.
5. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ. Impact of migraine and tension-type headache on lifestyle, consulting behaviour and medication use: a Canadian population survey. Can J Neuroi Sci. 1993;20:131-137.
6. Lipton RB, Stewart WF. Medical consultation for migraine. Neurology. 1994;44 (suppl 2):199. Abstract.
7. Rasmussen BK, Jensen R, Olesen J. Impact of migraine on sickness, absence and utilization of medical services: a Danish population study. J Epidemiol Community Health. 1992;46:443-446.
8. Micieli G. Suffering in silence. In: Edmeads J, ed. Migraine: A Brighter Future. Worthing, England: Cambridge Medical Publications; 1993:1-7.
9. Lipton RB, Stewart WF, Celentano DD, Reed M. Undiagnosed migraine: a comparison of symptom-based and physician diagnosis. Arch Intern Med. 1992;152:1273-1278.
10. Celentano DD, Stewart WF, Lipton RB, Reed ML. Medication use and disability among migraineurs: a national probability sample survey. Headache. 1992;32:223-228.
11. Stang PE, Osterhaus JT, Celentano DD. Migraine: patterns of healthcare use. Neurology. 1994;44(suppl 4):S47-S55.
12. Gilkey SJ, Ramadan NM. Use of over-the-counter drugs in migraine. CNS Drugs. 1996;6:83-88.
13. Lipton RB, Newman LC, Solomon S. Over-the-counter medication and the treatment of migraine. Headache. 1994;34:547-548.
14. Lipton RB, Solomon S, Sheftell FD. Medical consultation for migraine: results of the AASH Gallup Survey. Headache. 1995;35:563. Abstract.
15. Migliardi JR, Armellino JJ, Friedman M, Gillings DB, Beaver WT. Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther. 1994;56:576-586.
16. Laska EM, Sunshine A, Mueller F, Elvers WB, Siegel C, Rubin A. Caffeine as an analgesic adjuvant. JAMA. 1984;251:1711-1718.
17. Olesen J. A review of current drugs for migraine. J Neurol. 1991;238(suppl 1): S23-S27.
18. Solomon GD. Therapeutic advances in migraine. J Clin Pharmacol. 1993;33:200-209.
19. Stewart WF, Lipton RB. Population-based clinical trials in headache. In: Olesen J, Tfelt-Hansen P, eds. Headache Treatment: Trials Methodology and New Drugs. New York, NY: Raven Press; 1997:65-70.
20. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):19-28.
21. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831-2835.
22. Goadsby PJ, Zagami AS, Donnan GA, et al. Oral sumatriptan in acute migraine. Lancet. 1991;338:782-786.
23. Tokola RA, Kangasniemi P, Neuvonen PJ, Tokola O. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia. 1984;4:253-263.
24. Hakkarainen H, Parantainen J, Gothoni G, Vapaatalo H. Tolfenamic acid and caffeine: a useful combination in migraine. Cephalalgia. 1982;2:173-177.
25. Von Seggern RL, Adelman JU. Cost considerations in headache treatment, 2: acute migraine treatment. Headache. 1992;36:493-502.
26. Kumar KL, Cooney TG. Headaches. Med Clin North Am. 1995;79:264-271.